|
業務類別
|
Biotechnology |
|
業務概覽
|
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous systemdiseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its key product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications. |
| 公司地址
| 2222 Ponce de Leon Boulevard, Floor 3, Coral Gables, FL, USA, 33134 |
| 電話號碼
| +1 786 629-1376 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.relmada.com |
| 員工數量
| 17 |
| Mr. Charles S. Ence |
Chief Accounting and Compliance Officer |
美元 483.04K |
11/04/2025 |
| Mr. Paul Kelly |
Director and Chief Operating Officer |
-- |
06/01/2025 |
| Mr. Maged Shenouda |
Chief Financial Officer and Principal Accounting Officer |
美元 493.75K |
11/04/2025 |
| Dr. Sergio Traversa |
Chief Executive Officer and Director |
美元 750.72K |
11/04/2025 |
|
|
| Ms. Fabiana Fedeli |
Independent Director |
11/04/2025 |
| Mr. Paul Kelly |
Director and Chief Operating Officer |
06/01/2025 |
| Mr. John Glasspool |
Independent Director |
11/04/2025 |
| Dr. Sergio Traversa |
Chief Executive Officer and Director |
11/04/2025 |
| Mr. Charles J. Casamento |
Chairman of the Board |
11/04/2025 |
|
|
|
|
